Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TdcP-IPV vaccine
- Development stage
- Unknown
- Lead developer
- Daiichi Sankyo
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
TdcP-IPV is a combination vaccine designed for use as a booster in children, typically around 6 years of age, who have previously received primary immunization with diphtheria-tetanus-whole cell pertussis (DTwcP) and oral polio vaccine (OPV). The formulation contains tetanus toxoid, low dose diphtheria toxoid, a 5-component acellular pertussis antigen mix, and inactivated poliovirus. Its mechanism of action is to induce immunity against tetanus, diphtheria, pertussis (whooping cough), and poliomyelitis by stimulating the immune system to produce protective antibodies against these pathogens. Clinical studies have shown that the TdcP-IPV vaccine is immunogenic and safe when administered as a booster dose[5].
- Brand names
- Adacel PolioRepevax
- Other names
- TdcP-IPV vaccine
02
Targets
BCR (Immunoglobulin G B Cell Receptor)B-cell receptor specific for poliovirus type 2 capsid epitopesB-cell receptor specific for pertactin epitopesB-cell receptor specific for diphtheria toxoid epitopes
Beyond the preview
Go deeper on TdcP-IPV vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TdcP-IPV vaccine.